GlassScriptPhysician profile
Jessica M Ritch
NPI 1528221405
$3,101.87
in general payments reported to CMS, 2019-2025
36 companies · $408 in 2025
The $408 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $223 · 2021: $484 · 2022: $403 · 2023: $725 · 2024: $436 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,491 · Education: $77.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,491.13 |
| Education | $77.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $717.58 | 2019-2025 | Orilissa, Botox |
| Astellas Pharma US INC | $491.26 | 2019-2025 | Veozah, Myrbetriq |
| Intuitive Surgical, INC. | $210.75 | 2023 | Da Vinci Surgical System |
| Pfizer INC. | $181.86 | 2019-2024 | |
| Hologic Sales and Service, LLC | $174.97 | 2019-2025 | Aptima, Acessa Provu System, Affirm Prone Biopsy System |
| Evofem Biosciences, INC. | $152.01 | 2020-2025 | Phexxi, Solosec, Phexx |
| Therapeuticsmd, INC. | $111.90 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $106.71 | 2023-2025 | Myfembree, Gemtesa |
| Axonics, INC. | $103.74 | 2022-2024 | Axonics |
| Mayne Pharma Commercial LLC | $70.28 | 2023-2025 | |
| Coloplast Corp | $68.47 | 2019-2024 | |
| Lupin INC. | $47.09 | 2019-2021 | |
| Myovant Sciences INC. | $46.86 | 2021-2022 | |
| Medtronic, INC. | $46.00 | 2023-2024 | Interstim |
| Urovant Sciences INC | $45.33 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $44.51 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Meditrina | $44.12 | 2021 | |
| Integra Lifesciences Corporation | $43.00 | 2025 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Coopersurgical, INC. | $39.34 | 2020-2023 | Advincula Delineator Uterine Manipulator |
| Allergan, INC. | $31.97 | 2021-2022 | |
| Bluewind Medical | $31.07 | 2025 | Revi |
| Laborie Medical Technologies Corp. | $28.68 | 2023 | |
| 180 Medical, INC. | $28.40 | 2025 | Gentlecath |
| Valencia Technologies Corporation | $26.63 | 2023 | Ecoin Device Kit |
| Agile Therapeutics, INC. | $24.90 | 2021 | |
| Kerecis Limited | $22.76 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Duchesnay USA Incorporated | $22.54 | 2019 | |
| Organon LLC | $20.71 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.00 | 2019 | |
| Exeltis, USA INC. | $17.94 | 2022 | |
| Amag Pharmaceuticals, INC. | $16.71 | 2019 | |
| Merck Sharp & Dohme LLC | $16.40 | 2020 | |
| Ferring Pharmaceuticals INC. | $15.43 | 2019 | |
| Shield Therapeutics INC | $15.06 | 2024 | |
| Aspira Women'S Health INC | $11.17 | 2019 | |
| Boston Scientific Corporation | $7.72 | 2025 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Ritch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.